share_log

Arcutis Biotherapeutics | 8-K: Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Arcutis Biotherapeutics | 8-K: Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Arcutis Biotherapeutics | 8-K：Arcutis公佈2024年第三季度財務業績並提供業務最新情況
美股SEC公告 ·  2024/11/07 05:07

Moomoo AI 已提取核心訊息

Arcutis Biotherapeutics reported strong Q3 2024 financial results with total product revenues reaching $44.8M, representing 452% YoY and 45% QoQ growth. The revenue breakdown includes $22.0M from ZORYVE cream 0.3%, $20.3M from ZORYVE foam 0.3%, and $2.5M from ZORYVE cream 0.15%. The company achieved improved gross-to-net margins, now in the low 50% range, with total franchise unit demand increasing 25% QoQ.The FDA has accepted the supplemental New Drug Application for ZORYVE foam for scalp and body psoriasis treatment, with a PDUFA date of May 22, 2025. Additionally, Health Canada approved ZORYVE foam for seborrheic dermatitis, with commercial launch planned by end of 2024. The company has expanded Medicaid coverage to four additional states and secured coverage from major PBMs.The company maintained a strong financial position with $331.2M in cash and equivalents as of September 30, 2024. Net loss for Q3 was $41.5M ($0.33 per share), compared to $44.8M ($0.73 per share) in Q3 2023. Operating expenses included $19.5M for R&D and $58.8M for SG&A, with net cash used in operations improving by 23% compared to Q2 2024.
Arcutis Biotherapeutics reported strong Q3 2024 financial results with total product revenues reaching $44.8M, representing 452% YoY and 45% QoQ growth. The revenue breakdown includes $22.0M from ZORYVE cream 0.3%, $20.3M from ZORYVE foam 0.3%, and $2.5M from ZORYVE cream 0.15%. The company achieved improved gross-to-net margins, now in the low 50% range, with total franchise unit demand increasing 25% QoQ.The FDA has accepted the supplemental New Drug Application for ZORYVE foam for scalp and body psoriasis treatment, with a PDUFA date of May 22, 2025. Additionally, Health Canada approved ZORYVE foam for seborrheic dermatitis, with commercial launch planned by end of 2024. The company has expanded Medicaid coverage to four additional states and secured coverage from major PBMs.The company maintained a strong financial position with $331.2M in cash and equivalents as of September 30, 2024. Net loss for Q3 was $41.5M ($0.33 per share), compared to $44.8M ($0.73 per share) in Q3 2023. Operating expenses included $19.5M for R&D and $58.8M for SG&A, with net cash used in operations improving by 23% compared to Q2 2024.
Arcutis Biotherapeutics公佈了強勁的2024年第三季度財務業績，總產品營業收入達4480萬美元，同比增長452%，環比增長45%。營業收入細分包括ZORYVE 0.3%乳膏收入2200萬美元，ZORYVE 0.3%泡沫收入2030萬美元，以及ZORYVE 0.15%乳膏收入250萬美元。公司實現了改善的毛利淨率，目前在50%低區間，總特許經營單位需求環比增加25%。FDA已接受ZORYVE泡沫針對頭皮和身體銀屑病治療的補充新藥申請，PDUFA日期爲2025年5月22日。此外，加拿大衛生部批准ZORYVE泡沫用於脂溢性皮炎，計劃於2024年底進行商業推出。公司已將Medic...展開全部
Arcutis Biotherapeutics公佈了強勁的2024年第三季度財務業績，總產品營業收入達4480萬美元，同比增長452%，環比增長45%。營業收入細分包括ZORYVE 0.3%乳膏收入2200萬美元，ZORYVE 0.3%泡沫收入2030萬美元，以及ZORYVE 0.15%乳膏收入250萬美元。公司實現了改善的毛利淨率，目前在50%低區間，總特許經營單位需求環比增加25%。FDA已接受ZORYVE泡沫針對頭皮和身體銀屑病治療的補充新藥申請，PDUFA日期爲2025年5月22日。此外，加拿大衛生部批准ZORYVE泡沫用於脂溢性皮炎，計劃於2024年底進行商業推出。公司已將Medicaid覆蓋範圍擴展至四個額外州，並獲得主要PBM的覆蓋。截至2024年9月30日，公司的現金及等價物保持在33120萬美元，財務狀況強勁。第三季度淨虧損爲4150萬美元（每股0.33美元），而2023年第三季度爲4480萬美元（每股0.73美元）。營業費用包括研發1950萬美元和SG&A 5880萬美元，經營活動淨現金使用相比於2024年第二季度改善了23%。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間